Fludarabine is a purine analog antimetabolite that inhibits DNA synthesis. Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies.
- Mechanism
- Curator reviewed
Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite appears to act by inhibiting DNA polymerase alpha, ribonucleotide reductase and DNA primase, thus inhibiting DNA synthesis. The mechanism of action of this antimetabolite is not completely characterized and may be multi-faceted.
- Primary indication
- For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimenCurator reviewed · 2 structured indications
- Formula / weight
- C10H12FN5O4 · 285.235 g/mol (avg)
- First approval
- Canada, 2007 · United States, 1991
- Code names
- NSC-118218 · NSC-118218H
- Brand names
Resolves to
HBUBKKRHXORPQB-FJFJXFQQSA-NSMILESNC1=NC(F)=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1OWhat you can answer from here — as of September 21, 2026
Which drugs share a target with Fludarabine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account